Abstract
Introduction Antigen testing is essential in the clinical management of COVID-19. However, most evaluations of antigen tests have been performed before the emergence of the Omicron variant. Thus, an assessment of the diagnostic performance of antigen tests for the detection of SARS-CoV-2 during the circulation of Omicron variant is required.
Methods This prospective observational study evaluated QuickNavi-COVID19 Ag, a rapid antigen detection test between December 2021 and February 2022 in Japan, using real-time reverse transcription (RT)-PCR as a reference. Two nasopharyngeal samples were simultaneously collected for antigen testing and for RT-PCR. Variant analysis of the SARS-CoV-2 genomic sequencing was also performed.
Results In total, nasopharyngeal samples were collected from 1,073 participants (417 positive; 919 symptomatic; 154 asymptomatic) for analysis. Compared with those of RT-PCR, the sensitivity, specificity, positive predictive value, and negative predictive value were 94.2% (95% CI: 91.6%–96.3%), 99.5% (95% CI: 98.7%–99.9%), 99.2% (95% CI: 97.8%–99.8%), and 96.5% (95% CI: 94.8%–97.7%), respectively. The sensitivity among symptomatic individuals was 94.3% (95% CI: 91.5%–96.4%). Overall, 85.9% of sequences were classified as Omicron sublineage BA.1, 12.4% were Omicron sublineage BA.2, and 1.6% were Delta B.1.617.2. (Delta variant). Most of the samples (87.1%) had Ct values <25.
Conclusions The QuickNavi-COVID19 Ag test showed high diagnostic performance for the detection of the SARS-CoV-2 Omicron sublineages BA.1 and BA.2 from nasopharyngeal samples.
Competing Interest Statement
Denka Co., Ltd. provided funds for research expenses and the QuickNavi-Flu+COVID19 Ag and QuickNavi-COVID19 Ag tests without charge. Hiromichi Suzuki received a lecture fee from Otsuka Pharmaceutical Co., Ltd. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu work for Denka Co., Ltd., the developer of the QuickNavi-Flu+COVID19 Ag and QuickNavi-COVID19 Ag tests.
Funding Statement
Denka Co., Ltd. provided funds for research expenses and the QuickNavi-Flu+COVID19 Ag and QuickNavi-COVID19 Ag tests without charge. Hiromichi Suzuki received a lecture fee from Otsuka Pharmaceutical Co., Ltd. Daisuke Kato, Miwa Kuwahara and Shino Muramatsu work for Denka Co., Ltd., the developer of the QuickNavi-Flu+COVID19 Ag and QuickNavi-COVID19 Ag tests.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The ethics board of the University of Tsukuba Hospital approved the study (approval number: R03-042), including the method of obtaining informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
E-mail addresses of each author: Yuto Takeuchi, yuto-takeuchi{at}umin.ac.jp; Yusaku Akashi, yusaku-akashi{at}umin.ac.jp; Atsuo Ueda, atsuo.ueda06090727{at}outlook.jp; Yoshihiko Kiyasu, ykiyasu{at}md.tsukuba.ac.jp; Norihiko Terada, terada.norihiko.ck{at}ms.hosp.tsukuba.ac.jp; Yoko Kurihara, kurihara.yoko.fu{at}un.tsukuba.ac.jp; Daisuke Kato, daisuke-kato{at}denka.co.jp; Miwa Kuwahara, miwa-kuwahara{at}denka.co.jp; Shino Muramatsu, shino-muramatsu{at}denka.co.jp; Shigeyuki Notake, notake{at}tmch.or.jp; Koji Nakamura, koji-nakamura{at}tmch.or.jp;
Data Availability
All data produced in the present study are available upon reasonable request to the authors
